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1. Introduction 
     In this study, we carefully explore the causal relationship between length of stay (LOS) in 
hospitals and treatment outcome for acute myocardial infarction (AMI) patients in Japan. This is 
a controversial topic stemming from a serious concern regarding the rapidly expanding medical 
care expenditure in Japan. We focus on a unique Japanese feature to provide new quantitative 
evidence on the causal effect of LOS on treatment outcome, which is relevant to health 
economists and policymakers within and outside Japan. 
     Internationally, the health/medical aspects in Japan are considered to have efficient 
features. First, the general health status of the Japanese is well shaped, which is evident from the 
high life expectancy and the very low infant mortality (WHO, 2013).1 Second, health 
expenditure is relatively low in Japan. Both the relative proportion of total health expenditure to 
GDP and per capita expenditure in Japan are close to the average of OECD countries. Third, 
Japan established a mandatory health care system in 1961, providing universal medical coverage 
linked to jobs or regions of residency through employers or municipalities, where the 
government determines the national fee schedule (including drug fees) that is applicable to all 
providers. These characteristics illustrate that the Japanese population enjoys better health and 
longer life expectancy at a relatively lower cost of access to medical care for those who are 
insured. 
     In contrast to these aspects, the average length of stay in hospitals (ALOS)—which is 
often used as an indicator of health efficiency—is much longer in Japan as compared to other 
OECD countries (OECD, 2011). Figure 1 illustrates the cross-country comparison among 
OECD countries in terms of ALOS and curative (acute) care beds per 1,000 people (OECD, 
2013). The ALOS, for all causes, is 18.2 days in Japan, which is substantially higher than that in 
                                                   
1 By causes of mortality, the number of deaths per 100,000 people owing to AMI, cancer, or diabetes mellitus 
is much lower in Japan than the OECD average (OECD, 2013). In addition, risk factors related to daily 
smoking, overweight or obese population, and adult alcohol consumption is lower in the total Japanese 
population. 
OECD countries (7.5 days) and close to four times that in the US (4.8 days).2 On the other hand, 
the number of curative care beds per 1,000 people is 8.0 in Japan, which is much higher than the 
OECD average of 3.4; moreover, the ratio of practicing physicians per 1,000 people is 2.2, 
which is lower than the OECD average of 3.2.3  
     Owing to rapid aging in Japanese society, health expenditure has also been steadily 
increasing both in terms of the absolute and relative amounts to GDP; this is expected to expand 
further in the future with a larger proportion of the elderly having higher per capita expenditures 
(National Council on Social Security, 2006). The Japanese government considers the longer 
ALOS compared with other developed countries as one of the causes of the increasing medical 
expenditure in Japan, based on the observed positive correlation between per capita inpatient 
medical expenditure for the elderly and the ALOS among prefectures. Under the uniform 
fee-for-service system prevalent in hospitals, a longer hospitalization term appears justified 
since the “price” for hospitalization does not change. Indeed, according to OECD (2011), “[t]he 
abundant supply of beds and the structure of hospital payments in Japan provide hospitals with 
incentives to keep patients longer. Financial incentives inherent in hospital payment methods 
can also influence length of stay in other countries.” 
     The Japanese government has revised the fee-for-service schedule for either acute or 
chronic hospitals in order to encourage hospitals to discharge patients earlier. In 1991–92, the 
government increased a patient’s out-of-pocket hospitalization fee4, established a reward fee for 
shorter hospitalization, and introduced convalescent wards in a general hospital for long-term 
hospitalized patients. Moreover, in 1998, the government began to lower the hospitalization fee 
of general hospitals offering acute medical care if a patient aged 75 or over is hospitalized for 
over 90 days (Izumida, 2004; Yamamoto, 2004) and introduced the public long-term care 
insurance program in 2000. During this period, the ALOS—excluding that in chronic 
                                                   
2 For Japan, the ALOS data refers to ALOS for acute care, excluding long-term care beds in hospitals (OECD, 
2013). 
3 In contrast, the density of nurses is higher in Japan than the OECD average.  
4 The reform is legislated by the Revision of Law of Health and Medical Services for the Elderly (Rojin 
Hoken Hou).  
hospitals—substantially declined from 34.4 days in 1994 to 17.9 days in 2012, although it is still 
the longest in Japan among OECD countries.5  
     Further, the government and each prefecture was required to establish a “Plan for 
Effective Medical Expenditure” (Iryohi Tekiseika Keikaku) for the 2008–2013 period; the main 
objective of this plan is to reduce the ALOS so that the gap between the ALOS among 
prefectures and the shortest LOS among prefectures (Nagano Prefecture) is halved by 2015.6 In 
parallel with the change in incentives for hospitals, in 2003, the Diagnostic Procedure 
Combination (DPC)—an inpatient prospective payment system—was introduced for “special 
function hospitals”; this was considered the Japanese counterpart of the Medicare Prospective 
Payment System (PPS) in the US (Anderson and Ikegami, 2011), which aimed to reduce the 
variation in health expenditure and LOS across hospitals.7  
     While a reduction in the LOS in hospitals has been a focal point in medical reform in 
Japan, it is important to consider the effect of shorter LOS on treatment outcome, but not merely 
by relying on a simple “the shorter, the better” discussion that assumes that all other things are 
equal. A shorter LOS may reduce the cost per discharge and shift care from inpatient to less 
expensive post-acute settings (OECD, 2011). On the other hand, if a longer LOS contributes to a 
better treatment outcome, a shorter LOS may have an adverse effect on treatment outcome. 
Moreover, shorter LOS may need more intensive and costly services per day and could lower 
the comfort and recovery of the patient and increase the readmission rate, thereby resulting in a 
higher cost per episode of illness.8 
     Thus, when exploring the causal effect of LOS on treatment outcome, we need to consider 
                                                   
5 Izumida (2004) examined the effect of change in fee for hospital services on LOS in 1997, 1998, and 2000, 
and found that the 1997 and 1998 reforms affected the LOS in hospitals. 
6 The plan has a legal basis in the Act on Assurance of Medical Care for Elderly People (Koreisha no Iryo no 
Kakuho ni kansuru Horitsu), which has been effective from April 2008.  
7 Anderson and Ikegami (2011) summarized the following concerns on Japan’s DPC acute hospital payment 
system: (1) a hospital-specific conversion factor that adjusts payments made by the DPC system, (2) a 
significant proportion of payments that are made outside the DPC system, (3) the number of cases for which 
payment is made outside the DPC system, (4) the per day payment system, (5) specific adjustments based on 
hospital behavior, and (6) the auditing mechanisms. 
8 Tokunaga and Imanaka (2002) argue that aspects that determine patient satisfaction depend on the LOS in 
Japanese hospitals. 
the endogenous relationship. One direction for addressing this endogeneity is to focus on a 
“natural experiment,” which is represented by any policy or institutional changes. Evans et al. 
(2008) carefully examined the impact of state and federal laws designed to increase the length of 
postpartum hospital stay that substantially reduced the proportion of newborns discharged early. 
A simple OLS estimation revealed that a shorter postpartum hospital stay is correlated with 
better health since healthier babies are discharged sooner. In contrast, a 2SLS estimation using a 
series of laws changed in the late 1990s as instrumental variables revealed that an increase in the 
length of postpartum hospital stay is unrelated to the baby’s health. They concluded that the 
average effect of longer postpartum LOS on the probability of readmission is small, but it can be 
highly cost effective for high-risk babies. 
     To the best of our knowledge, no existing research in Japan explores the causal effect of 
LOS on treatment outcome. Extending the scope to recent studies outside Japan, Kociol et al. 
(2012) examined data on AMI patients from 17 countries and found a substantial variation in the 
30-day readmission rate and LOS across the countries (not including data from Japan); the 
30-day readmission rates were higher for the US than other countries, while the median LOS 
was shortest for US patients (3 days) and longest for Germany (8 days). Then, they found that 
the difference in the 30-day post-discharge readmission rate after ST-segment elevation 
myocardial infarction (STEMI) treatment across countries is greatly attenuated after adjustment 
for LOS. On the other hand, Saczynski et al. (2010) observed that LOS after AMI treatment 
significantly declined from 7.2 days to 5.0 days between 1995 and 2005 in the US; however, 
they found that a declining LOS is not associated with an increased risk for early readmission or 
all-cause mortality.9 
     In this study, we adopt an alternative approach to address the endogeneity issue to provide 
new persuasive evidence. Rokuyo is a label on Japanese calendars and pocket diaries that 
indicates one’s good or bad luck, direction, or fortune for each day. Rokuyo comprises six basic 
                                                   
9 The sample was 4,184 patients hospitalized with AMI in a central New England metropolitan area during 6 
annual periods (1995, 1997, 1999, 2001, 2003, 2005). The findings are not changed across year under study.  
labels that include Sensho, Tomobiki, Senbu, Butsumetsu, Taian, and Shakkou to indicate how 
auspicious a given day is.10 Rokuyo is a rather popular and prevalent superstition in Japan where 
most people know the statements on formal (ceremonial) occasions such as “a marriage party 
should not made on a Butsumetsu day” and “a funeral day should not take place on a Tomobiki 
day,” regardless of whether they believe this. Since AMI is an acute disease, a patient usually 
cannot choose a Rokuyo day on admission, but can do so for discharge. In other words, a patient 
who is going to be discharged can avoid a Butsumetsu (unlucky) day and even wait for the next 
Taian (lucky) day.  
     Indeed, subsequent sections show that the days of admission for AMI patients are random 
across Rokuyo, but those of discharge are clearly more concentrated on a Taian day and less on a 
Butsumetsu day. Thus, the Rokuyo day at the time of discharge is a valid instrument since it is 
related to LOS, but not related to treatment outcome. One might argue that a patient who 
suffered a serious heart attack is more likely to choose a good day for discharge, and thus, the 
Rokuyo day is not purely unrelated to treatment outcome. However, our data—which 
corresponds to the Cooperative Cardiovascular Project (CCP) in the US—provides a variety of 
indicators of the severity levels of AMI, which enable us to control for the seriousness of the 
AMI that a patient has undergone. Moreover, as we discuss below, the correlation coefficients 
between the discharge Rokuyo and explanatory variables are low—less than 0.1. 
     The remainder of this manuscript is organized in the following manner. In Section 2, we 
describe the data used in the estimation and provide evidence of the Rokuyo day on 
                                                   
10 The Japanese “roku” means “six”. The origin of Rokuyo is unclear but was imported from China to Japan 
in the 14th century. Interestingly, Rokuyo gained the popularity after the World War Second. The definition for 
each label is as follows (Takano et al. (2011) except Shakko). 
Butsumetsu: (the) Buddha's death; a very unlucky day according to traditional almanacs. 
Taian: a lucky [an auspicious] day (on the Japanese calendar). 
Senshou: a day on which bold actions are supposed to turn out well; a day supposed to be lucky in the 
morning and unlucky in the afternoon. 
Senbu: a day on which it is supposed to be better to avoid disputes and hurried actions; a day supposed to be 
unlucky in the morning and lucky in the afternoon. 
Tomobiki: a day on which one's bad luck is thought to affect one's friends, and which is therefore avoided 
when scheduling funerals 
Shakko: a day which is lucky during the hour of the horse (11 am–1 pm) but the luck is bad for the rest. 
admission/discharge. In Section 3, we conduct a regression analysis to explore the relationship 
between LOS and treatment outcome with alternative specifications. In Section 4, we provide 
various robustness checks on our main results. In Section 5, we present the conclusion. 
 
2. Data description and Rokuyo at admission and discharge 
     In Japan, it is fair to say that large-scale patient-level data that is internationally 
comparable is scarce. An exception is the Tokai Acute Myocardial Infarction Study (TAMIS), 
whose objective is to create a database comparable to the Cooperative Cardiovascular Project 
(CCP). The CCP is designed to improve the quality of care for Medicare beneficiaries with AMI. 
TAMIS aims to investigate the variation in the quality of healthcare with respect to treatments 
and outcomes between the US and Japan, controlling for chart-based detailed clinical 
information on AMI patients.11 In addition to rich information on individual characteristics, 
comorbidity and severity at admission, TAMIS provides data that is essential to this 
analysis—the dates of admission to and discharge from a hospital for each episode of illness, 
which enables us to identify on which Rokuyo day a patient was admitted and discharged.  
     The data collection enabled us to obtain abstracted charts pertaining to 3,274 heart attack 
patients who were newly hospitalized in 15 municipal or non-profit high-tech and high-volume 
general hospitals located in the Tokai area of Japan that provide coronary angiography (CAG) 
and percutaneous coronary intervention (PCI) between January 2001 and December 2003, the 
period when stent technology prevailed (called TAMIS-II Data)12. In the process of data 
collection, charts were carefully reviewed by research nurses and physicians in the standardized 
                                                   
11 The CCP is undertaken by the Health Care Financing Administration (HCFA, currently called Center for 
Medicare and Medicaid Services: CMS). See the detailed description of the TAMIS project in Noguchi et al. 
(2008). 
12 See Hirakawa et al. (2005), Hirakawa et al. (2006), and Kimata et al. (2008). The TAMIS project also 
collected data on AMI patients during the period 1995–1997 in the same manner. Noguchi et al. (2008) used 
data for the period 1995–1997 to explore factors for the extraordinarily frequent use of percutaneous 
transluminal coronary angioplasty (PTCA) for the treatment of AMI and found that the probability of 
receiving PTCA is affected by the density of medical resources in a region; moreover, they found that medical 
expenditure was higher for treated patients but that there are no significant differences in hospitalization days 
between those who were treated and those who were not, thereby implying that the frequent use of PTCA is 
economically motivated. 
manner of abstraction of medical records as done by the HCFA/CMS for the CCP. The record 
abstracts contain over 100 comorbid diseases and severity measures that collectively summarize 
all the major associated diseases and functional status impairments. Moreover, the abstracts 
include AMI severity measures following the CCP’s expert advisory panel, which influence the 
appropriateness of major AMI treatment decisions and health outcomes (Noguchi et al., 2008).  
     Table 1 presents the frequency of Rokuyo days at admission and discharge as well as 
ALOS. The data demonstrates that Rokuyo days are random at admission (Column 1) and the 
ALOS is comparable regardless on which Rokuyo day a patient was admitted (Column 2). Table 
2 presents the test statistics from the Kolmogorov–Smirnov test for equality of distribution of 
LOS by Rokuyo on admission and discharge days. As the table clearly shows, there is no 
significant difference in the distribution of LOS across Rokuyo on admission. On the contrary, 
the Rokuyo day of discharge is concentrated more on Taian, (21.9 percent) and less on 
Butsumetsu (13.2 percent) (Column (3) in Table 1). The pattern follows the ALOS by Rokuyo on 
discharge days (Column 4). The gap in the ALOS between Taian and Butsumetsu is 2.3 days. 
Further, Table 2 reveals that the distribution of LOS differs among some Rokuyo. In particular, 
the distribution of LOS on Taian is statistically different from that on Butsumetsu, Sensho, and 
Senpu. Further, that of Senpu is statistically different from Tomobiki in addition to Taian. 
     These observations demonstrate that the Rokuyo day of admission and the subsequent 
LOS are random. This is natural because a patient who has a heart attack needs to be 
hospitalized immediately and cannot wait to choose a suitable Rokuyo day for admission.13 In 
contrast, it is evident that discharge is more frequent on Taian and less so on Butsumetsu. The 
non-random variation stems from the fact that a patient can choose (or wait for) a good Rokuyo 
day for discharge even if he/she no longer requires hospitalization. According to modern science, 
Rokuyo is a superstition and the choice of Rokuyo does not affect the treatment outcome for 
                                                   
13 According to the guideline for AMI treatments, a doctor must make a diagnosis within 10 minutes after a 
patient arrives at the hospital, describe the treatment with the risks and benefits to the patient and family 
members, and begin treatment within 30 minutes (Uematsuse, 2002).  
AMI patients.  
     Table 3 reports the descriptive statistics of individual demographics. We excluded the 
observations with missing variables among the listed ones. Further, we also excluded the 
observations of those patients who passed away during hospitalization. The probability of 
rehospitalization within one year, which is the treatment outcome variable in this study, is 39.3 
percent. In this study, the definition of “rehospitalization” is the case in which a patient who 
received AMI treatment is readmitted within one year after discharge in the same hospital where 
the patient received the initial AMI treatment. If a patient passed away within one year after 
discharge, we considered this rehospitalization. It must be noted that we faced several issues 
related to the definition of rehospitalization. First, a patient may be re-hospitalized in a different 
hospital than the hospital where he/she received the initial treatment. In this case, we cannot 
trace the patient’s rehospitalization. However, as discussed subsequently, the average age of the 
patients in the data is 65. Hence, it is not very realistic to imagine that elderly patients who have 
undergone an episode of AMI frequently move away from the place where they used to stay. 
Therefore, the bias arising from this concern could be minimal, if any. Second, the data was 
collected at 15 high-tech and high-volume medical facilities located in the Tokai area of Japan. 
Thus, we do not have information on potential patients admitted to more small-scale facilities 
that may be characterized as low-tech and/or low-volume; this may create a sample selection 
bias. However, generally speaking, an AMI patient is admitted to a health facility that is 
equipped with a certain high level of technology. Hence, the issue of sample selection caused by 
this problem may not be very serious. Third, the one-year time window of rehospitalization is 
arbitrarily determined by the authors, although this time-window appears to be a standard length 
for research purposes. In robustness checks, we change the time-window of rehospitalization to 
six months, nine months, and two years to ascertain whether our main results are affected. 
Fourth, while we can trace the death of patients after discharge if that happens, information on 
the cause of the death was not collected. 
     The average age of patients is 65 years and males account for over three-fourths of the 
sample. By type of medical insurance, over 60 percent of the patients in the sample are 
beneficiaries of National Health Insurance (NHI), followed by Employee Health Insurance and 
Mutual Assistance Insurance. The number of family members living with a patient is more than 
two and more than three-fourths of the sample has a spouse. The ALOS is 19.63 days. As 
mentioned in the previous section, the Rokuyo day at discharge is concentrated on Taian (22.1 
percent), while that at admission is comparable across Rokuyo. 
     Table 4 reports the descriptive statistics of variables representing comorbidity and severity 
at admission. We converted all the information on comorbidity and severity at admission into 
dummy variables. The main reason for this is that in emergency cases such as AMI, it is difficult 
to collect all the detailed information on the patient, which may create many missing variables 
in the dataset. This would have forced us to exclude the observations on all such patients owing 
to missing data. To avoid this problem, we included “missing” as one category of dummy 
variables. Taking height as an example, approximately 20 percent (variable name: hei_y) of the 
patients’ height is “unknown,” which also makes it impossible to compute their Body Mass 
Index (BMI). Here, we use the word “unknown” and “missing” as synonyms. We face the 
choice of either excluding these observations or using a dummy variable for the missing variable, 
and adopt the latter method. As discussed earlier, one justification of using this method is rooted 
in practical reasoning. In emergency cases, collecting detailed information on patients is very 
difficult or occasionally even impossible. Thus, we interpreted the dummy variable representing 
missing data as information indicating the severity of a patient’s condition. We use these created 
dummies in the econometric analyses presented in the next section (McClellan and Noguchi, 
1997).  
Examining comorbidity variables at admission, most patients in the sample are totally 
continent (98.3 percent) and are able to walk independently (96.7 percent). By incidence of type 
of disease, the most prevalent is current cigarette smoker (over 50 percent), followed by 
hypertension (43.2 percent), and diabetes (any type, 27.8 percent). Moreover, 12.6 percent of the 
patients in the sample had CAG history and the proportion of PTCA history or CABG history 
was smaller. With regard to severity variables at admission, there is a non-negligible amount of 
missing data in temperature, mean arterial pressure (MAP), height, BMI, Albumin, EKG trace: 
transmural (new qwave), etc., thereby justifying using our dummy variable approach. Needless 
to say, myocardial infarction (MI) (excluding old MI) was detected by using EKG trace for 90 
percent of the patients; 17.4 percent of the patients had transmural q wave, while 22 percent of 
them had congestive heart failure. The proportion of patients whose highest creatinine level is 
25 or more was very small and the blood urea nitrogen level was normal for approximately 70 
percent of the patients (variable name: bunsun1).  
 
3. Estimation and results 
     In this section, we conduct a regression analysis to link LOS with treatment outcome. The 




iiliki zxy  210 ,     (1)  
 
where yi is the dependent variable and refers to the dummy variable that takes the value of one if 
a patient is re-hospitalized within one year after discharge, and zero otherwise. The explanatory 
variables can be divided into two categories: xi refers to the variables that indicate individual 
characteristics and health facility dummies (the variables shown in Table 3) and zi refers to 
comorbidity and severity variables on admission. The last term, i , is an error term.  
     Table 5 presents the estimation results based on a linear probability model using the OLS 
method.14 The model includes fixed effects at the health facility level and the standard errors 
are also clustered at the health facility level. Column (1) reports the coefficients on xi s, 
                                                   
14 The results reported in the section are not altered if we employ a probit estimation. 
excluding zi s from the explanatory variables. The coefficient on LOS is positive and significant, 
thereby indicating that the longer a patient is hospitalized, the higher the probability of 
rehospitalization. Column (2) shows the estimated coefficients on both xi s and zi s, including 
comorbidity and severity variables at admission in the explanatory variables. Again, the 
coefficient on LOS is positive and significant, thereby implying that the longer a patient is 
hospitalized, the higher the probability of rehospitalization is. No individual characteristics are 
significant once comorbidity and severity variables at admission are included. Some 
comorbidity variables at admission such as hypertension, angina, family medical history of 
ischemic heart disease, renal failure, and CABG history are found to be positively statistically 
significant, thereby implying that these comorbidities have a positive correlation with the 
probability of rehospitalization. Similarly, some severity variables at admission such as high 
MAP, low weight, high level of white blood cells, and congestive heart failure are positive and 
statistically significant, thereby implying that these comorbidities have a positive correlation 
with the probability of rehospitalization.  
     In sum, the OLS estimation shows a positive and significant relationship between LOS 
and rehospitalization probability. However, we cannot interpret these findings as the causal 
association between LOS and rehospitalization. The positive association may simply show that a 
patient with a higher rehospitalization probability is more likely to be discharged later15. 
Another case is that there might be an unobservable factor that affects both LOS and probability 
of rehospitalization simultaneously (i.e., omitted variable bias), while it appears that there is 
almost no possibility of bias caused by measurement error because the variable we are 
concerned about for this bias is LOS, which is accurately measured in the data. In any case, we 
have to address this reverse causality or a possible bias caused by unobservable factors in 
capturing the causal effect of LOS on treatment outcome. 
     Thus, we conduct the estimation using instrumental variables in order to address the 
                                                   
15 See Evans et al. (2008) for a similar positive relationship in the case of postpartum hospital days and health 
status of newborn babies. 
endogeneity issue between LOS and the readmission probability. The instrumental variables are 
Rokuyo days at admission and discharge, which was reviewed in Section 2. Conceptually, the 
discharge Rokuyo is a valid instrument that is related with LOS but not related with treatment 
outcome. Moreover, the correlation coefficients between the discharge Rokuyo (IV) and 
explanatory variables are low—less than 0.1 in absolute value (results are omitted to save space 
but available upon request). We include Rokuyo day at admission as an instrumental variable too 
because the discharge day is partially affected by the day of admission, and the Rokuyo day at 
admission might affect the choice if discharge day given the order of the Rokuyo days.16  
     We implement two-stage least squares (2SLS), two-step generalized method of moments 
(GMM), and limited information maximum likelihood (LIML) estimations. Before we discuss 
the results, it is important to note the following aspects. First, as our OLS results show, omitting 
comorbidity and severity variables at admission from the specification of the outcome equation 
may cause a severe omitted variable bias. Thus, we applied the three aforementioned estimation 
methods to the specifications that include these variables. Second, because we cluster the 
observations at health facility level, the number of clusters is much smaller than the sum of the 
number of exogenous regressors and that of excluded instruments. In such a circumstance, the 
covariance matrix of orthogonality conditions is not full rank and GMM and overidentification 
tests are infeasible since the weighting matrix cannot be calculated. To solve this problem, a 
sufficient number of exogenous regressors is “partialled out” from all the other variables in the 
estimation for the weighting matrix to have full rank. Further, according to the Frisch–Waugh–
Lovell (FWL) theorem (Frisch and Waugh, 1933; Lovell, 1963), in the two-step GMM 
estimation, the coefficients for the remaining regressors are the same as those that would be 
obtained if the variables were not partialled out when the coefficients of the partialled variables 
are not calculated. As a result of this procedure, in the results of the GMM estimation, we report 
                                                   
16 The order of the Rokuyo days is fixed in the following manner: Sensho, Tomobiki, Senbu, Butsumetsu, 
Taian, and Shakko. However, the first day of January and July is set to be Sensho, that of February and August 
is Tomobiki, that of March and September is Senbu, that of April and August is Butsumetsu, that of May and 
November is Taian, and that of June and December is Shakko (all months are included in the old (lunar) 
calendar). In other words, the Rokuyo day begins in each lunar month with the first day in the same order.  
only the coefficients of LOS—age, gender, number of family members living with a patient, and 
presence of spouse. This does not compromise the value of our approach because what we are 
interested in is the coefficient of LOS. Third, because there are numerous comorbidity and 
severity variables at admission, we do not report the coefficients of these variables. Although 
health facility dummies are included in the specification, they are omitted from the table.17  
     Table 6 reports the estimation results of the 2SLS, two-step GMM, and LIML as well as 
the result of the first stage of 2SLS. The dependent variable in the first stage is LOS, which is an 
endogenous variable in the second stage. The dummy for rehospitalization within one year is the 
dependent variable in the second stage. The result of the first stage of specification (1) indicates 
that the coefficient of Taian at discharge is positive and significant (base case is Butsumetsu). 
This implies that LOS on Taian discharge is longer than that on Butsumetsu discharge by 1.5 
days. We also notice that the coefficients on admission are not significant for any Rokuyo except 
Sensho, which is marginally and negatively significant at the 10 percent level. However, as we 
discussed in detail earlier, the Rokuyo at admission is conceptually random because a patient 
cannot choose when he/she is affected by AMI and cannot wait to be hospitalized once an 
episode occurs. Elderly and male patients are more likely to have longer LOS, while LOS tends 
to be shorter if the patient has a spouse. 
The F-value of the first stage is 12, which implies that the relevance of the instrument is 
still satisfied according to the Staiger–Stock rule of thumb (F > 10; Staiger and Stock, 1997). 
The reported Kleibergen–Paap Wald rank F statistic is 12.36, which again implies that weak 
identification is not to be considered a problem. Further, the Sargan–Hansen J statistic is 4.490 
and its p-value is 0.8763. Thus, the joint null hypothesis that the instruments are valid and that 
the excluded instruments are correctly excluded from the estimated equation cannot be rejected.  
     Examining the coefficients in the second stage of the estimation, the coefficient on LOS is 
not statistically significant. In contrast to the results in Table 5 using OLS, this observation 
                                                   
17 The full results are available on request from the authors. 
indicates that the difference in LOS across discharge Rokuyo does not affect rehospitalization 
probability. While the gap in LOS between Butsumetsu (base case) and Taian is 1.5 days in the 
first stage, the coefficient on LOS in the second stage is not statistically significant. This result is 
not altered even in specification using two-step GMM or LIML. 
     In sum, while the association between LOS and rehospitalization is statistically significant 
in the OLS estimation, the coefficient of LOS is no longer significant once the endogeneity is 
corrected by using Rokuyo as an instrumental variable. In other words, additional stay caused by 
the choice of preferable Rokuyo at discharge (by patients) does not have a causal effect on 
treatment outcome.  
 
4. Robustness checks 
We conducted two types of robustness checks. The first one was using a different time 
window for rehospitalization. In the main specification, we specified that a patient is considered 
rehospitalized if he/she was rehospitalized (or passed away) within one year after discharge. 
However, this one-year time window is slightly arbitrary. We re-estimate the same model by 
changing this time window for rehospitalization to six months, nine months, and two years. In 
the second robustness check, we use the log of LOS. As depicted in Figure 2, the distribution of 
LOS is skewed to the right; thus, in alternative specifications, we use log(LOS) instead of LOS. 
Figure 3 illustrates the distribution of log(LOS), which is closer to a normal distribution than 
LOS itself.  
Table 7 presents the results of these two robustness checks. The table reports the 
coefficient of LOS or log(LOS) in the second stage of the estimation. When log(LOS) is used, 
the results from the first stage of the estimation (not shown) are similar to those using LOS. In 
particular, the coefficient of Taian is positive and statistically significant. If the Rokuyo at 
discharge is Taian, the LOS is longer by 1.2 days than the LOS at discharge on Butsumetsu. 
Further, the F-value and Sargan–Hansen J statistic are 14.04 and 4.332 (P-value = 0.8882), 
respectively, thereby implying that the instruments are valid.  
     The table shows that the OLS estimation consistently indicates a positive relationship 
between LOS (or log(LOS)) and probability of rehospitalization, regardless of the time window 
of rehospitalization. On the other hand, once instrumented, such a positive relationship loses its 
significance. There is only one case—time window of six months for rehospitalization estimated 
by two-step GMM using LOS—where the relationship is negative and very marginally 
significant at the 10 percent level. However, in all other cases in 2SLS, two-step GMM, and 
LIML, the coefficient of LOS or log(LOS) are insignificant. Therefore, these robustness checks 
broadly support our main results. 
 
5. Conclusion 
     A long ALOS is one of the distinct characteristics of the Japanese medical care program. 
In this study, we carefully explored the causal relationship between LOS in hospitals and 
treatment outcome for AMI patients in Japan. We addressed the endogeneity between LOS and 
treatment outcome by using an exogenous variation in the Rokuyo days, which are found to be 
irrelevant to admission day but relevant to discharge day. While we did find a significant 
association between LOS and rehospitalization probability in the OLS estimation, we did not 
find a significant relationship once LOS is instrumented by the six basic labels in 2SLS, 
two-step GMM, and LIML estimations.  
     This implies that additional stay because of patient’s choice of preferred Rokuyo at 
discharge has no effect on rehospitalization probability. In particular, our result shows that the 
gap in the ALOS for a patient discharged on a Taian day and for a patient discharged on a 
Butsumetsu day is 1.5 days and the difference has no effect on rehospitalization probability. 
Our results suggest that there is room for improving efficiency in the use of medical 
resources. Whether a reduction in LOS contributes to reducing total medical costs depends not 
only on LOS but also on the supply of medical care services, including the number of beds as 
well as density of physicians and nurses. A subject for further research could be the 
consideration of any possible change in hospital behavior to maintain the revenue specified 
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Figure 1 Average length of stay, curative care beds, and physician density among OECD 
countries 
 
(Note) Data is taken from OECD Health Data 2013. The timing is 2011 or the closest year. 
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Table2: Kolmogorov-Smirnov test for equality of distribution of length of 
stay by Rokuyo on admission and discharge days 
      
Admission Butsumetsu Taian Shakko Sensho Tomobiki 
Taian 0.862 
    
Shakko 0.446 0.837 
   
Table 1: Rokuyo on admission and discharge days and the length of stay 
 




































































Total 3231           2942         
(Note) The sample used to compute length of stay excludes patients hospitalized for more than 180 days. 
Sensho 0.296 0.733 0.997 
  
Tomobiki 0.802 0.984 0.940 0.843 
 
Senpu 0.470 0.865 0.676 0.534 0.528 
      
Discharge Butsumetsu Taian Shakko Sensho Tomobiki 
Taian 0.009*** 
    
Shakko 0.772 0.139 
   
Sensho 0.969 0.041** 0.797 
  
Tomobiki 0.113 0.638 0.600 0.307 
 
Senpu 0.627 0.000*** 0.244 0.313 0.029** 
(Note)  
     
1. The sample to compute length of stay excludes a patient who is hospitalized 
more than 180 days. 







Table 3 Descriptive statistics (Individual demographics)
Variables # obs Mean S.D.
dum1: re-hospitalization dummy (within 1 year, =1 if re-hospitalized) 2690 0.393 0.488
Age 2690 65.090 11.327
P_1: Sex (=1 if male) 2690 0.784 0.411
iins1: type of medical insurance (National Health Insurance) 2690 0.639 0.480
iins2: type of medical insurance (Employees Health / Mutual Assistance Insurance) 2690 0.161 0.367
iins3: type of medical insurance (no insurance, 100% OOP) 2690 0.013 0.112
iins4: type of medical insurance (Government-managed insurance) 2690 0.096 0.294
iins5: type of medical insurance (Public assistance) 2690 0.010 0.098
iins6: type of medical insurance (Health Insurance Society) 2690 0.083 0.276
fam: Number of family members living with a patient 2690 2.152 1.605
spouse: Presence of spouse (=1 if yes) 2690 0.775 0.417
days_h: LOS 2690 19.631 15.418
rok1_d: Rokuyo  at discharge (Butsumetsu ) 2690 0.135 0.341
rok2_d: Rokuyo  at discharge (Taian ) 2690 0.221 0.415
rok3_d: Rokuyo  at discharge (Shakko ) 2690 0.152 0.359
rok4_d: Rokuyo  at discharge (Sensho ) 2690 0.172 0.377
rok5_d: Rokuyo  at discharge (Tomobiki ) 2690 0.170 0.375
rok6_d: Rokuyo  at discharge (Senbu ) 2690 0.151 0.358
rok1_h: Rokuyo  at admission (Butsumetsu ) 2690 0.170 0.376
rok2_h: Rokuyo  at admission (Taian ) 2690 0.173 0.379
rok3_h: Rokuyo  at admission (Shakko ) 2690 0.171 0.377
rok4_h: Rokuyo  at admission (Sensho ) 2690 0.161 0.368
rok5_h: Rokuyo  at admission (Tomobiki ) 2690 0.161 0.368
rok6_h: Rokuyo  at admission (Senbu ) 2690 0.163 0.370
_IFA_1_2 : hospital 2 dummy 2690 0.041 0.197
_IFA_1_3 : hospital 3 dummy 2690 0.095 0.293
_IFA_1_4 : hospital 4 dummy 2690 0.113 0.316
_IFA_1_5 : hospital 5 dummy 2690 0.089 0.285
_IFA_1_6 : hospital 6 dummy 2690 0.025 0.157
_IFA_1_7 : hospital 7 dummy 2690 0.011 0.103
_IFA_1_8 : hospital 8 dummy 2690 0.032 0.177
_IFA_1_9 : hospital 9 dummy 2690 0.095 0.293
_IFA_1_10 : hospital 10 dummy 2690 0.038 0.192
_IFA_1_11 : hospital 11 dummy 2690 0.085 0.279
_IFA_1_12 : hospital 12 dummy 2690 0.036 0.186
_IFA_1_13 : hospital 13 dummy 2690 0.151 0.358
_IFA_1_14 : hospital 14 dummy 2690 0.024 0.154
_IFA_1_15 : hospital 15 dummy 2690 0.126 0.332
 Table 4: Descriptive statistics (Comorbidity variables and severity variables at admission)
Variables # obs Mean S.D. Min Max
(1) Comorbidity variables at admission
uri1: Continence: totally continent 2960 0.983 0.130 0 1
uri2: Continence: occasionally incontinent 2960 0.010 0.102 0 1
uri3: Continence: no urine output 2960 0.001 0.039 0 1
uri4: Continence: unknown 2960 0.005 0.072 0 1
walk1: Mobility: Walks Independently 2960 0.966 0.181 0 1
walk2: Mobility: Walks with assistance 2960 0.022 0.146 0 1
walk3: Mobility: Unable to walk 2960 0.008 0.090 0 1
walk4: Mobility: unknown 2960 0.004 0.061 0 1
X_1y: Hypertension 2960 0.432 0.495 0 1
X_1d: Hypertension: unknown 2960 0.000 0.000 0 0
Y_1y: Hyperlipemia 2960 0.175 0.380 0 1
Y_1d: Hyperlipemia: unknown 2960 0.000 0.019 0 1
Z_1y: Diabetes （any type） 2960 0.278 0.448 0 1
Z_1d: Diabetes （any type）: unknown 2960 0.000 0.000 0 0
AA_1y: Diabetes treated by insulin 2960 0.038 0.191 0 1
AA_1d: Diabetes treated by insulin: unknown 2960 0.728 0.445 0 1
AB_1y:  Angina 2960 0.123 0.329 0 1
AB_1d:  Angina: unknown 2960 0.000 0.019 0 1
AD_1y: Cardiac heart failure or pulmonary edema 2960 0.030 0.172 0 1
AD_1d: Cardiac heart failure or pulmonary edema: unknown 2960 0.000 0.019 0 1
AF_1y: Old myocadial infarction 2960 0.098 0.297 0 1
AF_1d: Old myocadial infarction: unknown 2960 0.000 0.000 0 0
AH_1y: Current cigarette smoker 2960 0.533 0.499 0 1
AH_1d: Current cigarette smoker: unknown 2960 0.001 0.033 0 1
AJ_1y: Arrhythmia 2960 0.054 0.225 0 1
AJ_1d: Arrhythmia: unknown 2960 0.000 0.019 0 1
AK_1y: Family medical history of schemic heart disease 2960 0.087 0.282 0 1
AK_1d: Family medical history of schemic heart disease: unknown 2960 0.000 0.019 0 1
AL_1y: Renal failure 2960 0.019 0.136 0 1
AL_1d: Renal failure: unknown 2960 0.000 0.000 0 0
AM_1y: Cirrhosis 2960 0.004 0.061 0 1
AM_1d: Cirrhosis: unknown 2960 0.000 0.019 0 1
AN_1y: Cerebrovascular accident: Cerebral infarction 2960 0.090 0.286 0 1
AN_1d: Cerebrovascular accident: Cerebral infarction: unknown 2960 0.000 0.000 0 0
AO_1y: Cerebrovascular accident: Brain hemorrhage 2960 0.012 0.108 0 1
AO_1d: Cerebrovascular accident: Brain hemorrhage: unknown 2960 0.007 0.086 0 1
AP_1y: Cerebrovascular accident: Subarachnoid hemorrhage 2960 0.006 0.074 0 1
AP_1d: Cerebrovascular accident: Subarachnoid hemorrhage: unknown 2960 0.007 0.084 0 1
AQ_1y: COPD 2960 0.010 0.102 0 1
AQ_1d: COPD: unknown 2960 0.000 0.000 0 0
AR_1y: Aneurysm of aorta 2960 0.012 0.107 0 1
AR_1d: Aneurysm of aorta: unknown 2960 0.000 0.000 0 0
AS_1y: Ulcus pepticum 2960 0.094 0.292 0 1
AS_1d: Ulcus pepticum: unknown 2960 0.000 0.000 0 0
AT_1y: Cancer 2960 0.044 0.206 0 1
AT_1d: Cancer: unknown 2960 0.000 0.000 0 0
AU_1y: Autoimmune disease 2960 0.017 0.130 0 1
AU_1d: Autoimmune disease: unknown 2960 0.000 0.000 0 0
AV_1y: Drug allergy/med reaction 2960 0.053 0.224 0 1
AV_1d: Drug allergy/med reaction: unknown 2960 0.000 0.000 0 0
AW_1y: Dementia/alzheimer's disease 2960 0.017 0.128 0 1
AW_1d: Dementia/alzheimer's disease: unknown 2960 0.000 0.000 0 0
AX_1y: Terminal illness 2960 0.001 0.039 0 1
AX_1d: Terminal illness: unknown 2960 0.000 0.019 0 1
AY_1y: CAG history 2960 0.126 0.332 0 1
AY_1d: CAG history: unknown 2960 0.000 0.019 0 1
AZ_1y: PTCA history 2960 0.086 0.280 0 1
AZ_1d: PTCA history:unknown 2960 0.000 0.019 0 1
BA_1y: CABG history 2960 0.010 0.102 0 1
BA_1d: CABG history: unknown 2960 0.000 0.019 0 1
(2) Severerity variables at admission
Heart rate
admspls0: =1 if heart rate < 60 2960 0.102 0.303 0 1
admspls1: =1 if 60 <= heart rate < 80 2960 0.417 0.493 0 1
admspls2: =1 if 80 <= heart rate < 100 2960 0.351 0.477 0 1
admspls3: =1 if 100 <= heart rate < 120 2960 0.094 0.292 0 1
admspls4: =1 if 120 <= heart rate < 150 2960 0.023 0.151 0 1
admspls5: =1 if 150 <= heart rate 2960 0.002 0.047 0 1
admspls_y: =1 if heart rate unknown 2960 0.010 0.098 0 1
Temperature
admtmp1: =1 if temperature > 38.3 2960 0.002 0.047 0 1
admtmp2: =1 if 35.8 <= temperature < 38.3 2960 0.726 0.446 0 1
admtmp3: =1 if temperature < 35.8 2960 0.191 0.394 0 1
admtmp_y: =1 if temperature unknown 2960 0.081 0.272 0 1
 Table 4 (continued): Descriptive statistics (Comorbidity variables and severity variables at admission)
Variables # obs Mean S.D. Min Max
MAP(mean arterial pressure)
map0: =1 if MAP < 60 2960 0.019 0.138 0 1
map1: =1 if 60 <= MAP < 80 2960 0.205 0.404 0 1
map2: =1 if 80 <= MAP < 100 2960 0.411 0.492 0 1
map3: =1 if 100 <= MAP < 120 2960 0.236 0.425 0 1
map4: =1 if 120 <= MAP < 150 2960 0.062 0.241 0 1
map5: =1 if 150 <= MAP 2960 0.003 0.058 0 1
map_y: =1 if MAP unknown 2960 0.063 0.243 0 1
Height (cm)
hei0: =1 if hei < 140 2960 0.007 0.082 0 1
hei1: =1 if 140 <= hei < 150 2960 0.076 0.265 0 1
hei2: =1 if 150 <= hei < 160 2960 0.200 0.400 0 1
hei3: =1 if 160 <= hei < 170 2960 0.374 0.484 0 1
hei4: =1 if 170 <= hei < 180 2960 0.142 0.350 0 1
hei5: =1 if 180 <= hei 2960 0.006 0.074 0 1
hei_y: =1 if height unknown 2960 0.195 0.396 0 1
Weight (kg)
wei0: =1 if wei < 40 2960 0.019 0.136 0 1
wei1: =1 if 40 <= wei < 50 2960 0.100 0.301 0 1
wei2: =1 if 50 <= wei < 60 2960 0.230 0.421 0 1
wei3: =1 if 60 <= wei < 70 2960 0.261 0.439 0 1
wei4: =1 if 70 <= wei < 80 2960 0.138 0.345 0 1
wei5: =1 if 80 <= wei < 90 2960 0.045 0.206 0 1
wei6: =1 if 90 <= wei 2960 0.017 0.131 0 1
wei_y: =1 if weight unknown 2960 0.000 0.000 0 0
BMI
bmi0: =1 if bmi < 18.5 2960 0.047 0.212 0 1
bmi1: =1 if 18.5 <= bmi < 25 2960 0.500 0.500 0 1
bmi2: =1 if 25 <= bmi < 30 2960 0.213 0.409 0 1
bmi3: =1 if 30 <= bmi 2960 0.030 0.170 0 1
bmi_y: =1 if BMI unknown 2960 0.211 0.408 0 1
Glucose
admglu0: =1 if admglu < 50 2960 0.002 0.043 0 1
admglu1: =1 if 50 <= admglu < 250 2960 0.833 0.373 0 1
admglu2: =1 if 250 <= admglu < 400 2960 0.104 0.305 0 1
admglu3: =1 if 400 <= admglu < 600 2960 0.014 0.120 0 1
admglu4: =1 if 600 <= admglu 2960 0.001 0.033 0 1
admglu_y: =1 if Glucose unknown 2960 0.046 0.209 0 1
Albumin
admalb0: =1 if admalb < 2 2960 0.003 0.058 0 1
admalb1: =1 if 2 <= admalb < 5 2960 0.845 0.362 0 1
admalb2: =1 if 5 <= admalb 2960 0.016 0.124 0 1
admalb_y: =1 if Albumin unknown 2960 0.136 0.343 0 1
Highest creatinine
admlcre9_1y: =1 if Highest creatinine >= 25 2960 0.001 0.027 0 1
admlcre9_1d: Highest creatinine unknown 2960 0.034 0.182 0 1
Hematocrit
admhemac0: =1 if admhemac < 20 2960 0.006 0.074 0 1
admhemac1: =1 if 20 <= admhemac < 25 2960 0.010 0.098 0 1
admhemac2: =1 if 25 <= admhemac < 30 2960 0.035 0.185 0 1
admhemac3: =1 if 30 <= admhemac < 35 2960 0.151 0.358 0 1
admhemac4: =1 if 35 <= admhemac < 55 2960 0.776 0.417 0 1
admhemac5: =1 if 55<= admhemac 2960 0.003 0.058 0 1
admhemac_y: =1 if Hematocrit unknown 2960 0.019 0.136 0 1
White blood cells  (unit:000)
admwbc0: =1 if admwbc < 1000 2960 0.000 0.019 0 1
admwbc1: =1 if 1000 <= admwbc < 15000 2960 0.899 0.301 0 1
admwbc2: =1 if 15000 <= admwbc 2960 0.094 0.292 0 1
admwbc_y: =1 if White blood cells unknown 2960 0.006 0.079 0 1
Platelets  (unit:0000) 
admlplt0: =1 if admlplt < 20 2960 0.425 0.494 0 1
admlplt1: =1 if 20 <= admlplt < 100 2960 0.557 0.497 0 1
admlplt2: =1 if 100 <= admlplt < 500 2960 0.012 0.108 0 1
admlplt3: =1 if 500 <= admlplt 2960 0.000 0.000 0 0
admlplt_y: =1 if Platelets unknown 2960 0.006 0.079 0 1
Blood urea nitrogen 
bunsun0: =1 if bunsun < 10 2960 0.069 0.254 0 1
bunsun1: =1 if 10 <= bunsun < 20 2960 0.681 0.466 0 1
bunsun2: =1 if 20 <= bunsun < 30 2960 0.182 0.386 0 1
bunsun3: =1 if 30 <= bunsun 2960 0.058 0.234 0 1
bunsun_y: =1 if Blood urea nitrogen unknown 2960 0.010 0.100 0 1
CH_1y: EKG trace: MI /injury (excluding old MI) 2960 0.896 0.305 0 1
CH_1d: EKG trace: MI /injury (excluding old MI): unknown 2960 0.000 0.000 0 0
CJ_1y: EKG trace: transmural (new qwave) MI 2960 0.174 0.379 0 1
CJ_1d: EKG trace: transmural (new qwave) MI: unknown 2960 0.271 0.445 0 1
CK_1y: EKG trace: old/remote MI 2960 0.041 0.198 0 1
CK_1d: EKG trace: old/remote MI: unknown 2960 0.000 0.019 0 1
CL_1y: EKG trace: ventricular tachycardia/flutter 2960 0.154 0.361 0 1
CL_1d: EKG trace: ventricular tachycardia/flutter: unknown 2960 0.001 0.027 0 1
CM_1y: EKG trace: atrial fibrillation/flutter 2960 0.089 0.285 0 1
CM_1d: EKG trace: atrial fibrillation/flutter: unknown 2960 0.001 0.027 0 1
CN_1y: EKG trace: LBBB 2960 0.014 0.120 0 1
CN_1d: EKG trace: LBBB: unknown 2960 0.001 0.027 0 1
CO_1y: EKG trace: RBBB 2960 0.059 0.235 0 1
CO_1d: EKG trace: RBBB: unknown 2960 0.001 0.027 0 1
CP_1y: EKG trace: left fascicular blocks 2960 0.010 0.098 0 1
CP_1d: EKG trace: left fascicular blocks: unknown 2960 0.001 0.033 0 1
CQ_1y: EKG trace: heart block, 2nd/3rd degree 2960 0.055 0.229 0 1
CQ_1d: EKG trace: heart block, 2nd/3rd degree: unknown 2960 0.001 0.027 0 1
CS_1y: CHF (congestive heart failure) /pulmonary edema on chest X rays 2960 0.220 0.414 0 1
CS_1d: CHF (congestive heart failure) /pulmonary edema on chest X rays: unknown 2960 0.002 0.043 0 1
CW_1y: Stress test suggests ischemia 2960 0.011 0.105 0 1
CW_1d: Stress test suggests ischemia: unknown 2960 0.846 0.361 0 1
 Table 5: OLS estimation using Rokuyo
Dependent variable: Rehospitalization dummy (within 1 year, =1 if rehospitalized) coefficient S.E. coefficient S.E.
(A) Individual demograraphics
days_h: LOS 0.0031 0.0009 *** 0.0024 0.0008 ***
Age 0.0014 0.0011 0.0012 0.0012
P_1: Sex (=1 if male) -0.0267 0.0220 -0.0158 0.0272
iins1: type of medical insurance (National Health Insurance) [base case] - -  
iins2: type of medical insurance (Employees Health / Mutual Assistance Insurance) -0.0003 0.0212 -0.0022 0.0261
iins3: type of medical insurance (no insurance, 100% OOP) -0.0771 0.0871 -0.0425 0.0901
iins4: type of medical insurance (Government-managed insurance) -0.0357 0.0400 ** -0.0260 0.0403
iins5: type of medical insurance (Public assistance) 0.0344 0.0954 0.0508 0.0807
iins6: type of medical insurance (Health Insurance Society) -0.0216 0.0303 *** -0.0207 0.0338
fam: Number of family members living with a patient 0.0047 0.0032 0.0048 0.0034
spouse: Presence of spouse (=1 if yes) 0.0272 0.0188 0.0199 0.0196
_IFA_1_1 : hospital 1 dummy [base sase] - -  - -
_IFA_1_2 : hospital 2 dummy -0.3799 0.0113 *** -0.3308 0.0250 ***
_IFA_1_3 : hospital 3 dummy -0.2107 0.0123 *** -0.1671 0.0217 ***
_IFA_1_4 : hospital 4 dummy -0.0256 0.0122 ** -0.0388 0.0167 **
_IFA_1_5 : hospital 5 dummy -0.5599 0.0129 *** -0.4836 0.0413 ***
_IFA_1_6 : hospital 6 dummy -0.0637 0.0088 *** -0.0508 0.0200 **
_IFA_1_7 : hospital 7 dummy -0.0750 0.0130 *** -0.0708 0.0252 ***
_IFA_1_8 : hospital 8 dummy -0.3816 0.0099 *** -0.4089 0.0294 ***
_IFA_1_9 : hospital 9 dummy -0.4539 0.0128 *** -0.4244 0.0266 ***
_IFA_1_10 : hospital 10 dummy -0.3025 0.0068 *** -0.3085 0.0291 ***
_IFA_1_11 : hospital 11 dummy -0.6407 0.0104 *** -0.6033 0.0281 ***
_IFA_1_12 : hospital 12 dummy -0.3498 0.0097 *** -0.2941 0.0264 ***
_IFA_1_13 : hospital 13 dummy -0.5702 0.0113 *** -0.5765 0.0174 ***
_IFA_1_14 : hospital 14 dummy -0.6730 0.0165 *** -0.6687 0.0272 ***
_IFA_1_15 : hospital 15 dummy -0.5034 0.0085 *** -0.5023 0.0191 ***
(B) Cormobidity variables at admission
uri1: Continence: totally continent 0.0885 0.2871
uri2: Continence: occasionally incontinent 0.0913 0.3362
uri3: Continence: no urine output - -
uri4: Continence: unknown 0.1207 0.3167
walk1: Mobility: Walks Independently 0.1300 0.0726 *
walk2: Mobility: Walks with assistance 0.0310 0.0783
walk3: Mobility: Unable to walk - -
walk4: Mobility: unknown 0.0282 0.1490
X_1y: Hypertension 0.0496 0.0129 ***
X_1d: Hypertension: unknown - -
Y_1y: Hyperlipemia 0.0371 0.0262
Y_1d: Hyperlipemia: unknown -0.3261 0.1013 ***
Z_1y: Diabetes （any type） -0.0635 0.0658
Z_1d: Diabetes （any type）: unknown - -
AA_1y: Diabetes treated by insulin -0.0011 0.0656
AA_1d: Diabetes treated by insulin: unknown -0.0957 0.0727
AB_1y:  Angina 0.0625 0.0263 **
AB_1d:  Angina: unknown 0.9595 0.0702 ***
AD_1y: Cardiac heart failure or pulmonary edema 0.0697 0.0823
AD_1d: Cardiac heart failure or pulmonary edema: unknown -0.3111 0.1178 ***
AF_1y: Old myocadial infarction 0.0203 0.0423
AF_1d: Old myocadial infarction: unknown - -
AH_1y: Current cigarette smoker -0.0174 0.0112
AH_1d: Current cigarette smoker: unknown 0.0612 0.0880
AJ_1y: Arrhythmia -0.0320 0.0353
AJ_1d: Arrhythmia: unknown 0.4061 0.0781 ***
AK_1y: Family medical history of schemic heart disease 0.0456 0.0264 *
AK_1d: Family medical history of schemic heart disease: unknown -0.2400 0.0620 ***
AL_1y: Renal failure -0.1552 0.0714 **
AL_1d: Renal failure: unknown - -
AM_1y: Cirrhosis -0.0044 0.1490
AM_1d: Cirrhosis: unknown -0.2624 0.0904 ***
AN_1y: Cerebrovascular accident: Cerebral infarction 0.0073 0.0327
AN_1d: Cerebrovascular accident: Cerebral infarction: unknown - -
AO_1y: Cerebrovascular accident: Brain hemorrhage 0.1708 0.1136
AO_1d: Cerebrovascular accident: Brain hemorrhage: unknown -0.2373 0.0994 **
AP_1y: Cerebrovascular accident: Subarachnoid hemorrhage -0.1122 0.0436 **
AP_1d: Cerebrovascular accident: Subarachnoid hemorrhage: unknown 0.3670 0.0971 ***
AQ_1y: COPD -0.0051 0.0746
AQ_1d: COPD: unknown - -
AR_1y: Aneurysm of aorta 0.0465 0.0716
AR_1d: Aneurysm of aorta: unknown - -
AS_1y: Ulcus pepticum 0.0073 0.0280
AS_1d: Ulcus pepticum: unknown - -
AT_1y: Cancer 0.0746 0.0586
AT_1d: Cancer: unknown - -
AU_1y: Autoimmune disease 0.0428 0.0933
AU_1d: Autoimmune disease: unknown - -
AV_1y: Drug allergy/med reaction 0.0154 0.0444
AV_1d: Drug allergy/med reaction: unknown - -
AW_1y: Dementia/alzheimer's disease -0.1609 0.0601 ***
AW_1d: Dementia/alzheimer's disease: unknown - -
AX_1y: Terminal illness 0.3441 0.0722 ***
AX_1d: Terminal illness: unknown -0.1664 0.1544
AY_1y: CAG history -0.1071 0.0379 ***
AY_1d: CAG history: unknown - -
AZ_1y: PTCA history 0.0919 0.0509 *
AZ_1d: PTCA history:unknown - -
BA_1y: CABG history 0.1637 0.0769 **
BA_1d: CABG history: unknown - -
Column (2)Column (1)
Table 5 (continued): OLS estimation using Rokuyo
Dependent variable: Rehospitalization dummy (within 1 year, =1 if rehospitalized) coefficient S.E. coefficient S.E.  
(C ) Sererity variables on admission
Heart rate
admspls0: =1 if heart rate<60 -0.0835 0.0504 *
admspls1: =1 if 60<=heart rate<80 -0.1111 0.0355 ***
admspls2: =1 if 80<=heart rate<100 -0.1305 0.0361 ***
admspls3: =1 if 100<=heart rate<120 -0.1242 0.0450 ***
admspls4: =1 if 120<=heart rate<150 -0.0799 0.0574
admspls5: =1 if 150<=heart rate 0.0804 0.2813
admspls_y: =1 if heart rate unknown - -
Temperature
admtmp1: =1 if temperature>38.3 - -
admtmp2: =1 if 35.8<=temperature<38.3 -0.0521 0.1536
admtmp3: =1 if temperature<35.8 -0.0557 0.1538
admtmp_y: =1 if temperature unknown -0.0046 0.1485
MAP(mean arterial pressure)
map0: =1 if MAP<60 - -
map1: =1 if 60<=MAP<80 0.1286 0.0837
map2: =1 if 80<=MAP<100 0.1448 0.0887
map3: =1 if 100<=MAP<120 0.1179 0.0950
map4: =1 if 120<=MAP<150 0.1218 0.0787
map5: =1 if 150<=MAP 0.4019 0.1611 **
map_y: =1 if MAP unknown 0.0544 0.0926
Hight (cm)
hei0: =1 if hei<140 0.0104 0.1946
hei1: =1 if 140<=hei<150 0.1247 0.0962
hei2: =1 if 150<=hei<160 0.1518 0.0710 **
hei3: =1 if 160<=hei<170 0.1399 0.0739 *
hei4: =1 if 170<=hei<180 0.1290 0.0798
hei5: =1 if 180<=hei - -
hei_y: =1 if height unknown 0.0699 0.0702
Weight (kg)
wei0: =1 if wei<40 0.1800 0.0963 *
wei1: =1 if 40<=wei<50 0.1412 0.0664 **
wei2: =1 if 50<=wei<60 0.1304 0.0638 **
wei3: =1 if 60<=wei<70 0.1213 0.0734 *
wei4: =1 if 70<=wei<80 0.1134 0.0862
wei5: =1 if 80<=wei<90 0.0725 0.1151
wei6: =1 if 90<=wei 0.0946 0.1294
wei_y: =1 if weight unknown - -
BMI
bmi0: =1 if bmi<18.5 -0.1220 0.1350
bmi1: =1 if 18.5<=bmi<25 -0.0758 0.0750
bmi2: =1 if 25<=bmi<30 -0.0674 0.0625
bmi3: =1 if 30<=bmi - -
bmi_y: =1 if BMI unknown 0.0713 0.1483
Glucose
admglu0: =1 if admglu<50 - -
admglu1: =1 if 50<=admglu<250 -0.1164 0.1549
admglu2: =1 if 250<=admglu<400 -0.0513 0.1465
admglu3: =1 if 400<=admglu<600 -0.1816 0.1586
admglu4: =1 if 600<=admglu 0.2967 0.2477
admglu_y: =1 if Glucose unknown -0.1318 0.1571
Albumin
admalb0: =1 if admalb<2 - -
admalb1: =1 if 2<=admalb<5 0.0522 0.1906
admalb2: =1 if 5<=admalb 0.0317 0.1878
admalb_y: =1 if Albumin unknown 0.1007 0.1940
Highest creatinine
admlcre9_1y: =1 if Highest creatinine>=25 0.0462 0.3265
admlcre9_1d: Highest creatinine unknown -0.0262 0.0585
Hematocrit
admhemac0: =1 if admhemac<20 -0.0134 0.1813
admhemac1: =1 if 20<=admhemac<25 -0.1672 0.1037
admhemac2: =1 if 25<=admhemac<30 -0.0720 0.1193
admhemac3: =1 if 30<=admhemac<35 -0.0797 0.1047
admhemac4: =1 if 35<=admhemac<55 -0.0523 0.0910
admhemac5: =1 if 55<=admhemac - -
admhemac_y: =1 if Hematocrit unknown 0.0155 0.1422
White blood cells  (unit:000)
admwbc0: =1 if admwbc<1000 - -
admwbc1: =1 if 1000<=admwbc<15000 0.4536 0.1118 ***
admwbc2: =1 if 15000<=admwbc 0.4819 0.1237 ***
admwbc_y: =1 if White blood cells unknown 0.2952 0.1116 ***
Platelets  (unit:0000) 
admlplt0: =1 if admlplt<20 0.1514 0.1138
admlplt1: =1 if 20<=admlplt<100 0.1470 0.1086
admlplt2: =1 if 100<=admlplt<500 0.0127 0.1130
admlplt3: =1 if 500<=admlplt - -
admlplt_y: =1 if Platelets unknown - -
Blood urea nitrogen 
bunsun0: =1 if bunsun<10 - -
bunsun1: =1 if 10<=bunsun<20 0.0565 0.0233 **
bunsun2: =1 if 20<=bunsun<30 0.0323 0.0235
bunsun3: =1 if 30<=bunsun 0.1119 0.0754
bunsun_y: =1 if Blood urea nitrogen unknown 0.0569 0.0866
CH_1y: EKG trace: MI /injury (excluding old MI) 0.0382 0.0305
CH_1d: EKG trace: MI /injury (excluding old MI): unknown - -
CJ_1y: EKG trace: transmural (new qwave) MI -0.0040 0.0245
CJ_1d: EKG trace: transmural (new qwave) MI: unknown 0.0289 0.0373
CK_1y: EKG trace: old/remote MI 0.0017 0.0558
CK_1d: EKG trace: old/remote MI: unknown -0.4338 0.0940 ***
CL_1y: EKG trace: ventricular tachycardia/flutter 0.0151 0.0257
CL_1d: EKG trace: ventricular tachycardia/flutter: unknown 0.9343 0.0988 ***
CM_1y: EKG trace: atrial fibrillation/flutter -0.0590 0.0345 *
CM_1d: EKG trace: atrial fibrillation/flutter: unknown - -
CN_1y: EKG trace: LBBB 0.0230 0.0620
CN_1d: EKG trace: LBBB: unknown - -
CO_1y: EKG trace: RBBB 0.0417 0.0340
CO_1d: EKG trace: RBBB: unknown 0.0000 (omitted)
CP_1y: EKG trace: left fascicular blocks -0.0712 0.0744
CP_1d: EKG trace: left fascicular blocks: unknown -0.2730 0.0796 ***
CQ_1y: EKG trace: heart block, 2nd/3rd degree -0.0202 0.0318
CQ_1d: EKG trace: heart block, 2nd/3rd degree: unknown - -
CS_1y: CHF (congestive heart failure) /pulmonary edema on chest X rays 0.0619 0.0248 **
CS_1d: CHF (congestive heart failure) /pulmonary edema on chest X rays: unknown -0.4512 0.0229 ***
CW_1y: Stress test suggests ischemia 0.0129 0.0489
CW_1d: Stress test suggests ischemia: unknown 0.0615 0.0308 **
Constant 0.6223 0.0752 *** -0.3276 0.5090
R-squared 0.2029 0.2520
Number of observations 2690 2690
(Note) ***, **, and * indicate significance at the 1%, 5% and 10% levels.
  
Table 6: 2SLS, 2-Step GMM, and LIML estimation using Rokuyo
  Coefficient S.E. Coefficient S.E. Coefficient S.E.  Coefficient S.E.
days_h: LOS - -  0.0058 0.0080  0.004 0.015  0.0023 0.0131
Age 0.0550 0.0274 ** 0.0009 0.0017 *** 0.001 0.001  0.0012 0.0013
P_1: Sex (=1 if male) 2.3516 0.5277 *** -0.0286 0.0236  -0.020 0.056  -0.0155 0.0470
iins1: type of medical insurance (National Health Insurance) [base case] - -  - - - -  - -
iins2: type of medical insurance (Employees Health / Mutual Assistance Insurance) 0.0338 0.5979 0.0025 0.0170  - -  -0.0022 0.0248
iins3: type of medical insurance (no insurance, 100% OOP) -2.7166 2.3065 -0.0730 0.0819 - -  -0.0428 0.0927
iins4: type of medical insurance (Government-managed insurance) -2.2318 1.1688  -0.0267 0.0361 ** - -  -0.0262 0.0398
iins5: type of medical insurance (Public assistance) 4.9694 2.3074 ** 0.0149 0.0922 - - 0.0515 0.0966
iins6: type of medical insurance (Health Insurance Society) -0.7949 1.2016 -0.0189 0.0271 *** - - -0.0208 0.0298
fam: Number of family members living with a patient -0.2399 0.1532 0.0053 0.0034  0.005 0.004 0.0047 0.0052
spouse: Presence of spouse (=1 if yes) -2.3047 0.8644 *** 0.0350 0.0277 0.024 0.032 0.0196 0.0344
rok1_d: Rokuyo  at discharge (Butsumetsu ) - - - -
rok2_d: Rokuyo  at discharge (Taian ) 1.5477 0.7480 ** - - - -
rok3_d: Rokuyo  at discharge (Shakko ) -0.0844 1.1907 - - - -
rok4_d: Rokuyo  at discharge (Sensho ) 0.8670 1.1458 - - - -
rok5_d: Rokuyo  at discharge (Tomobiki ) 0.3916 0.7717 - - - -
rok6_d: Rokuyo  at discharge (Senbu ) 0.3095 0.6779 - - - -
rok1_h: Rokuyo  at admission (Butsumetsu ) - - - - - -
rok2_h: Rokuyo  at admission (Taian ) 0.0520 1.1098 - - - -
rok3_h: Rokuyo  at admission (Shakko ) -1.8235 1.0951 - - - -
rok4_h: Rokuyo  at admission (Sensho ) -1.4883 0.7869 * - - - -
rok5_h: Rokuyo  at admission (Tomobiki ) -1.1554 0.8582 - - - -
rok6_h: Rokuyo  at admission (Senbu ) -0.5031 0.8704 - - - -
Constant 19.2471 11.1911 0.750 0.213 *** - - 0.3514 0.3662
R-squared
F value
Kleibergen-Paap Wald rk F statistic
Sargan-Hansen J statistic [P-value]
Number of observations
(Note) 
1: Standard errors are clustered at health facility level. ***, **, and * indicate significance of the 1%, 5%, and 10% levels.





Specification (1) Specification (2)






First stage Second stage Second stage




Coefficient S.E. Coefficient S.E. Coefficient S.E. Coefficient S.E.
6 months 0.0021 0.0007 *** -0.0008 0.0076 -0.0083 0.0048 * -0.0036 0.0145
9 months 0.0019 0.0008 ** -0.0013 0.0081 -0.0030 0.0046 -0.0025 0.0112
1 year 0.0024 0.0008 *** 0.0058 0.0080  0.0043 0.0154 0.0023 0.0131
2 years 0.0020 0.0009 ** 0.0063 0.0086 0.0111 0.0069 0.0079 0.0120
6 months 0.0699 0.0179 *** 0.0767 0.1932 0.1331 0.1200 0.0808 0.3091
9 months 0.0705 0.0208 *** 0.0082 0.1689 -0.0166 0.1218 -0.0094 0.2171
1 year 0.0761 0.0202 *** 0.0739 0.1831 -0.0176 0.1283 0.0733 0.2382
2 years 0.0689 0.0228 *** 0.1414 0.2137 0.1090 0.1615 0.1614 0.2707




2SLS Two step GMM
